08:39 AM EDT, 03/13/2026 (MT Newswires) -- (Updates with Novo Nordisk's ( NVO ) response in the third paragraph.)

Viatris' ( VTRS ) Mylan unit withdrew all its claims disputing Novo Nordisk's ( NVO ) assertions that Mylan's generic semaglutide medication infringes the patent covering Wegovy, according to federal court filings.

US District Judge Colm Connolly said Wednesday that following the withdrawal, Mylan cannot obtain regulatory approvals for its semaglutide drug until the expiration of Wegovy's '343 patent on Dec. 5, 2031, "and any additional period of pediatric exclusivity for the '343 Patent to which Novo Nordisk ( NVO ) has or may become entitled."

"As this case is ongoing, we cannot provide any further comment," Novo Nordisk ( NVO ) said in an emailed statement.

Viatris ( VTRS ) didn't immediately reply to a request for comment from MT Newswires.

Viatris ( VTRS ) shares fell 1.8% in Thursday trading, and Novo Nordisk ( NVO ) dropped 1.7%.